CommercialCoverageMedium impact
Ibalizumab-uiyk (Trogarzo) (CPB 0936, reviewed 2025-12-30)
Aetna·Infectious Disease, Internal Medicine·Medical Policy
Effective date
Dec 30, 2025
We identified it
Aug 15, 2026
Summary
Aetna has issued a fresh clinical policy (CPB 0936, effective 2025-12-30) establishing medical necessity criteria for ibalizumab-uiyk (Trogarzo), a CD4-directed post-attachment HIV inhibitor. Coverage requires patients to be 18+, treatment-experienced (6+ months), failing current antiretroviral therapy, with viral load >1,000 copies/mL and documented resistance to at least one drug from each of three antiretroviral classes (NRTI, NNRTI, PI). Billing teams must verify all criteria are met before processing claims for HCPCS code J1746.
Action Required
By 2025-12-30: Billing team must implement pre-authorization workflow for HCPCS code J1746 (ibalizumab-uiyk injection). Before processing claims, verify and document all five medical necessity criteria in the patient record: (1) age ≥18 years, (2) viral load >1,000 copies/mL, (3) documented resistance to at least one NRTI, at least one NNRTI, and at least one PI (per resistance testing), (4) ≥6 months prior antiretroviral treatment history, (5) current therapy failure or recent failure within 8 weeks. Update billing system to require submission of resistance testing documentation and viral load results with all J1746 claims for Aetna members. Route all J1746 claims to clinical review team to confirm eligibility before adjudication. Train billing and prior auth staff on the three antiretroviral drug classes and verification process. Update encounter forms and charge capture tools to include medical necessity checklist. Claims submitted without documented evidence of all criteria will be denied.